Encoded Therapeutics
Home
Our Science
⟵
⟵ Back
Overview
Genetic Medicines Product Engine
Pipeline & Programs
⟵
⟵ Back
Overview
Pipeline
Clinical Studies
ETX101 for Dravet Syndrome
Research Areas
Publications & Presentations
Patient
Community
⟵
⟵ Back
Overview
Patient Community Stories
Dravet Syndrome
Pre-Approval Access Statement
Healthcare
Professionals
About
News
⟵
⟵ Back
Overview
Press Releases
Media Kit
Careers
Contact
Encoded Therapeutics
News
Careers
Contact
Home
Our Science
Overview
Genetic Medicines Product Engine
Pipeline &
Programs
Overview
Pipeline
Clinical Studies
ETX101 for Dravet Syndrome
Research Areas
Publications & Presentations
Patient
Community
Overview
Patient Community Stories
Dravet Syndrome
Pre-Approval Access Statement
Healthcare
Professionals
About
Overview
Leadership
Board of Directors
Investors
Developing a One-time Gene Therapy for Dravet Syndrome
Post navigation
Previous:
From Gene Replacement to Gene Regulation: Developing a Disease-Modifying AAV Gene Therapy Vector for SCN1A-Positive (SCN1A+) Dravet Syndrome
Next:
Introducción a ETX101: Terapia de regulación génica para síndrome de Dravet SCN1A positive